行情

ASRT

ASRT

Assertio医疗
NASDAQ

实时行情|Nasdaq Last Sale

0.7684
-0.0407
-5.03%
已收盘, 16:07 11/14 EST
开盘
0.8044
昨收
0.8091
最高
0.8329
最低
0.7600
成交量
113.13万
成交额
--
52周最高
5.80
52周最低
0.7010
市值
6,199.53万
市盈率(TTM)
-1.0047
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ASRT 新闻

  • 沪指周跌2.46% 隔夜美联储官员密集讲话
  • 新浪财经.2小时前
  • 看中国论坛:双11是彰显中国消费信心的窗口
  • 新浪财经.7小时前
  • 美国家庭债务规模创纪录高位 四张图带你详细了解
  • 新浪财经综合.7小时前
  • 西铁城精机在中国建新厂生产自动车床 产能翻番
  • 新浪财经综合.8小时前

更多

所属板块

制药
-0.36%
制药与医学研究
-0.27%

热门股票

名称
价格
涨跌幅

ASRT 简况

Assertio Therapeutics, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), Cambia (diclofenac potassium for oral solution), Xartemis XR and Zipsor (diclofenac potassium). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia (PHN). Its Cambia (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.
展开

Webull提供Assertio Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。